Otsuka acquisition of Transcend for $1.23B signals expansion of methylone drug development for PTSD and anxiety

Otsuka is moving to acquire Transcend Therapeutics in a $1.23B deal, positioning the company to scale methylone-based drug development. Transcend’s lead candidate TSND-201 is framed as a methylone program, with development focused on PTSD, generalized anxiety disorder (GAD), and major depressive disorder (MDD). The article notes that recruitment is underway for a Phase 3 PTSD study (EMPOWER-1) where patients receive methylone or placebo in a once-weekly dosing schedule, with an additional follow-up period after the 4-week treatment phase. The piece also connects the decision to prior Phase 2 results and the company’s trial design and reporting, including mention of long dosing sessions and half-life, and it outlines the deal structure: $700M upfront plus $525M tied to sales milestones, expected to close in Q2.